Galmed Pharmaceuticals Stock Forum

TrytosaveabitOP : Inventiva said the Phase 2 proof-of-concept study met its primary endpoint with an absolute reduction of HbA1c of 1.14% to 1.59% in patients treated with lanifibranor or in combination with empagliflozin at week 24 versus an increase of 0.26% in the placebo arm.
Patients treated with the combination also were able to maintain a stable weight throughout the 24 weeks of the study.

Tom2808 : So this is bad news...

TrytosaveabitOP Tom2808: Yes in the short term! Investors were hoping to have that information by EOY or so? Now it’s going to be 6+ months according to that PR. GL

Tom2808 TrytosaveabitOP: I will come back and buy it 6 month later then

T-24Century : what pump and dump

TrytosaveabitOP T-24Century: I thought at first? But it was getting great volume for a AH P&D? So I thought as long as it’s left alone it would break a buck

TrytosaveabitOP T-24Century: But when I seen games being played, I scaled half at .76. GL